CADTH recommends that pemigatinib should not be reimbursed by public drug plans for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. The clinical evidence reviewed by CADTH was not strong enough to show whether treatment with pemigatinib benefits patients with CCA. It is not known if pemigatinib would lead to better outcomes for patients compared to treatments that are currently available. Patients identified a need for treatments that improve tumour response, delay disease progression, and improve quality of life. It is not clear whether pemigatinib meets these needs.

Clinical evidence suggests that Dupixent should be reimbursed to treat patients aged 12 years and older with severe asthma and with a type 2 or eosinophilic phenotype or oral corticosteroid–dependent asthma. Economic evidence suggests that a 93% price reduction is needed to ensure Dupixent is cost-effective at a $50,000 per quality-adjusted life-year threshold relative to standard of care alone. Cost-effectiveness versus other biologics is unknown. CADTH was unable to estimate the budget impact due to a high degree of uncertainty.

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection. Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses liraglutide 6 mg/mL (Saxenda). Indication under review : Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dunorubicin and cytarabine liposome for injection, 44 mg daunorubicin and 100 mg cytarabine per vial, IV infusion Indication: Treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes

CADTH recommends that Tecartus should be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) after 2 or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor if certain conditions are met. Tecartus should only be reimbursed if prescribed as a one-time therapy by experienced specialists in centres delivering cellular therapies, and the cost of Tecartus is reduced. Tecartus should only be covered to treat patients with R/R MCL who have received treatment with a BTK inhibitor (ibrutinib or acalabrutinib) and are in a clinically reasonable health status to tolerate the treatment.

CADTH recommends that Abecma should not be reimbursed by public drug plans for the treatment of multiple myeloma. Evidence from a clinical trial suggested that Abecma is associated with an improvement in response rate in patients with heavily treated multiple myeloma. No conclusions could be drawn for other important outcomes, including duration of response, overall survival, progression-free survival, and quality of life. Patients identified a need for treatments that can prolong remission and improve quality of life and symptoms, and that have fewer side effects. It is not clear whether Abecma meets these needs.

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses larotrectinib (Vitrakvi); 25 mg and 100 mg capsules (as larotrectinib sulphate) and 20 mg/mL oral solution (as larotrectinib sulphate). Indication: For the treatment of adult and pediatric patients with solid tumours that: have an NTRK gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity have no satisfactory treatment options